BioCentury | Apr 15, 2013
Clinical News

NeuroCell-PD data

...and glial cells. Pig neurons were found to have extended axons into the patient's brain. Diacrin Inc....
BioCentury | Oct 24, 2005
Company News

GenVec deal

...an undisclosed newly formed company. GNVC, which gained the program via its 2003 merger with Diacrin Inc....
BioCentury | Jan 5, 2004
Finance

Short-term performance

...$233 Maxygen (MAXY) $479 $879 $401 84% $329 Dendreon (DNDN) $209 $369 $160 77% $370 Diacrin...
BioCentury | Aug 25, 2003
Company News

GenVec, Diacrin deal

...18.1 million DCRN shares outstanding. GNVC closed Friday at $2.21. GenVec Inc. (GNVC), Gaithersburg, Md. Diacrin Inc....
BioCentury | May 26, 2003
Finance

Big bounce

...PGNX) Cancer, Infectious diseases $14.04 $9.86 236% Pharming (NASD-EU:PHAR) Biomanufacturing, Metabolic, Cardiovascular E1.34 E0.94 235% Diacrin...
BioCentury | Apr 28, 2003
Finance

Ebb & Flow

...the expanded deal. GNVC now stands valued at $60.8 million. GNVC's merger partner also benefited. Diacrin...
BioCentury | Apr 21, 2003
Company News

Diacrin, GenVec deal

...take the company through 2006. The deal is expected to close in the third quarter. Diacrin Inc....
BioCentury | Apr 21, 2003
Finance

Ebb & Flow

...on the week, is slated to release earnings this week (see "On Deck"). Buyout watch Diacrin...
BioCentury | Apr 15, 2003
Top Story

GenVec to acquire Diacrin

Gene therapy company GNVC will acquire cell transplantation company DCRN in a stock transaction valued at $40.4 million. GNVC will gain DCRN's cash and equivalents, which totaled $44.9 million as of Dec. 31, 2002. The...
BioCentury | Nov 18, 2002
Company News

Diacrin board of directors update

Diacrin Inc. (DCRN), Charlestown, Mass. Business: Gene/Cell therapy, Neurological Resigned: Henri Termeer WIR Staff...
Items per page:
1 - 10 of 69
BioCentury | Apr 15, 2013
Clinical News

NeuroCell-PD data

...and glial cells. Pig neurons were found to have extended axons into the patient's brain. Diacrin Inc....
BioCentury | Oct 24, 2005
Company News

GenVec deal

...an undisclosed newly formed company. GNVC, which gained the program via its 2003 merger with Diacrin Inc....
BioCentury | Jan 5, 2004
Finance

Short-term performance

...$233 Maxygen (MAXY) $479 $879 $401 84% $329 Dendreon (DNDN) $209 $369 $160 77% $370 Diacrin...
BioCentury | Aug 25, 2003
Company News

GenVec, Diacrin deal

...18.1 million DCRN shares outstanding. GNVC closed Friday at $2.21. GenVec Inc. (GNVC), Gaithersburg, Md. Diacrin Inc....
BioCentury | May 26, 2003
Finance

Big bounce

...PGNX) Cancer, Infectious diseases $14.04 $9.86 236% Pharming (NASD-EU:PHAR) Biomanufacturing, Metabolic, Cardiovascular E1.34 E0.94 235% Diacrin...
BioCentury | Apr 28, 2003
Finance

Ebb & Flow

...the expanded deal. GNVC now stands valued at $60.8 million. GNVC's merger partner also benefited. Diacrin...
BioCentury | Apr 21, 2003
Company News

Diacrin, GenVec deal

...take the company through 2006. The deal is expected to close in the third quarter. Diacrin Inc....
BioCentury | Apr 21, 2003
Finance

Ebb & Flow

...on the week, is slated to release earnings this week (see "On Deck"). Buyout watch Diacrin...
BioCentury | Apr 15, 2003
Top Story

GenVec to acquire Diacrin

Gene therapy company GNVC will acquire cell transplantation company DCRN in a stock transaction valued at $40.4 million. GNVC will gain DCRN's cash and equivalents, which totaled $44.9 million as of Dec. 31, 2002. The...
BioCentury | Nov 18, 2002
Company News

Diacrin board of directors update

Diacrin Inc. (DCRN), Charlestown, Mass. Business: Gene/Cell therapy, Neurological Resigned: Henri Termeer WIR Staff...
Items per page:
1 - 10 of 69